Back to search

University of Southampton

CD40 antibodies for the treatment of human malignancy

Abstract

dc:description.abstract

<p>This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours including transformed human B cell lines (RL and Daudi), human epithelial cell lines (MG79 [ovarian] and Cask [cervical]) and primary human B cell non-Hodgkin’s lymphomas obtained, with consent, from patients undergoing excision lymph mode biopsy or splenectomy.</p> <p>The ligation of CD40, on transformed human B cell lines, using Chinese hamster ovary cells transfected to express human CD40L and human soluble CD40L has shown significant cellular growth inhibition (p<0.001). Ligation of CD40 on human epithelial cell lines using human soluble CD40L has also resulted in significant growth inhibition.</p> <p>In primary B cell human non-Hodgkin’s lymphomas ligation of CD40 with both CD40L expressing CHO cells and human soluble CD40L in the presence of human IL4 has caused significant cellular proliferation (p<0.001) and induced upregulation of cell surface and costimulatory molecules including CD80, CD86, CD58, CD54.</p> <p>Anti-tumour activity has been identified in a xenograft model of a transformed human B cell line (Daudi) treated with both a mouse anti-human CD40 antibody and a chimeric human anti-CD40 antibody.</p> <p>I have performed important preclinical toxicology studies testing mouse anti-CD40 (3/23) by injecting the antibody intraperitoneally or intravenously in to BALB/c mice. The mice have been culled following treatment and a reversible dose dependent transaminitis associated with microscopic evidence of a reversible lympho-granulomatous hepatitis, that at the highest dose levels is acutely necrotising, has been identified. These anti-CD40 antibody toxicology studies are essential before a protocol for a phase I trial of human anti-CD40 antibody against CD40 expressing human tumours is developed.</p> <p>I have developed a new chimeric human anti-CD40 antibody containing human constant regions and mouse variable regions. This antibody is currently undergoing large scale production for a proposed trial to treat patients with CD40 expressing tumours (excluding low-grade non-Hodgkin’s lymphoma) who have failed conventional therapies.</p>

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2002

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Harvey, Melanie Louise

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Harvey, Melanie Louise. CD40 antibodies for the treatment of human malignancy. doctoral thesis, University of Southampton, 2002.